AstraZeneca : La Chine conduit à une guidance prudente
>Une fin d’année décevante au niveau des ventes t de la marge - AstraZeneca vient de publier ses résultats du T4 2019 qui s’avèrent décevants que ce soit au niveau des ventes et de la marge. Malgré une dynamique de croissance toujours solide (hausse de 9% à tcc sur ses ventes lors de ce trimestre), les derniers lancements ont fait moins bien qu’attendu. En effet, Tagrisso sort -4% en dessous des attentes, Lynparza -2% vs Cs et Imfinzi -7% vs Cs. Cette déception est co...AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.